Global Pediatric Neuroblastoma Treatment Market to grow with a CAGR of 8.58%
Increasing healthcare infrastructure and a supportive regulatory
environment are the major drivers for the Global Pediatric Neuroblastoma
Treatment Market.
According to TechSci Research report, “Global Pediatric Neuroblastoma
Treatment Market Industry Size, Share, Trends, Competition, Opportunity and
Forecast, 2018-2028”, Global
Pediatric Neuroblastoma Treatment Market has valued at USD 1.40 billion in 2022
and is anticipated to witness an impressive growth in the forecast period with
a CAGR of 8.58% through 2028. This can be due to collaborations and
partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market.
Globalization of healthcare is a factor that can drive the demand for the
Global Pediatric Neuroblastoma Treatment Market. The globalization of
healthcare refers to the increasing interconnectedness and collaboration among
healthcare systems, providers, and patients on a global scale. Globalization
allows patients and families to access specialized pediatric neuroblastoma
treatment centers and expertise from around the world. Patients may seek
treatment in countries or regions known for their excellence in pediatric
oncology. International collaboration in clinical trials and research is common
in pediatric oncology, including neuroblastoma. Patients in different countries
may have opportunities to participate in cutting-edge clinical trials, which
can drive demand for these treatments. Families from countries with limited
healthcare resources may travel internationally to receive pediatric
neuroblastoma treatment. This medical tourism can stimulate demand for
treatments offered in more advanced healthcare systems. Healthcare
professionals and researchers worldwide share knowledge and expertise in the
diagnosis and treatment of pediatric neuroblastoma. This global exchange of
information can lead to improved treatment protocols and outcomes. Telemedicine
technologies enable remote consultations between patients, families, and
healthcare providers. This allows for the exchange of medical opinions and
treatment recommendations, regardless of geographic distance. Globalization can
facilitate the import and export of medications and therapies. Pediatric
neuroblastoma patients may gain access to drugs and treatments that are not
available in their home countries.
Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on " Global Pediatric Neuroblastoma Treatment Market.”
Pediatric Neuroblastoma Treatment refers to the set of medical interventions
and therapies aimed at managing and potentially curing neuroblastoma, a cancer
that predominantly affects children. Surgical removal of the tumor is often the
initial step if it is accessible without posing undue risks. Surgeons aim to
remove as much of the tumor as possible while preserving healthy tissue and
function. High-dose chemotherapy and radiation therapy can damage healthy bone
marrow cells. Stem cell transplantation, either from the patient (autologous)
or a donor (allogeneic), may be performed to restore healthy blood cell
production. Supportive care measures address the side effects and complications
of treatment. This includes managing pain, nausea, fatigue, and providing
nutritional support.
In February 2023, The Pan American Health Organization (PAHO), in
collaboration with St. Jude Children’s Research Hospital and Childhood Cancer
International, has initiated a new campaign with the goal of informing parents,
caregivers, and healthcare professionals in Latin America and the Caribbean
about the initial signs of the most prevalent cancers in children and
adolescents. The objective is to enhance the early detection and treatment
outcomes of these cancers. Named 'Support Kids with Cancer,' the campaign was
launched in anticipation of International Childhood Cancer Day, observed on
February 15th. Its primary aim is to promote awareness of common pediatric
cancers such as lymphoblastic leukemia, Hodgkin lymphoma, and retinoblastoma.
The campaign underscores recognizable symptoms, including fatigue, unexplained
bruising, swelling or lumps, loss of appetite, persistent headaches, dizziness,
vomiting, and bone pain.
Drug access and affordability are significant
challenges in the Global Pediatric Neuroblastoma Treatment Market. Many cancer
drugs used in pediatric neuroblastoma treatment are originally developed for
adults. The availability of age-appropriate pediatric formulations is limited,
which can make dosing and administration challenging. Some of the newer and
more effective therapies for pediatric neuroblastoma, including targeted
therapies and immunotherapies, can be expensive. The high cost of these drugs
can pose a significant financial burden on patients and their families. In
regions with limited access to health insurance or government-funded healthcare
programs, families may struggle to cover the costs of pediatric neuroblastoma
treatment, including the cost of medications. Access to healthcare and
medications can vary widely from one region to another. In some areas,
specialized pediatric oncology centers and advanced treatments may be limited,
leading to disparities in care. Neuroblastoma treatment can be prolonged and
may require multiple rounds of chemotherapy, radiation therapy, and
immunotherapy. The cumulative costs of these treatments, including medications,
can be substantial. Access to clinical trials, which may offer innovative and
potentially more affordable treatment options, can be limited, particularly for
patients in underserved regions. Some drugs used in pediatric neuroblastoma
treatment may have orphan drug status, which can lead to higher prices due to
the limited patient population.
Global Pediatric Neuroblastoma Treatment Market
is segmented based on Treatment Type, End-User, and by region.
Based on Treatment Type, Global Pediatric
Neuroblastoma Treatment Market is segmented into Chemotherapy, Immunotherapy,
Radiation Therapy, and Others. Radiation
therapy, also known as radiotherapy, is a medical treatment that uses
high-energy radiation to target and destroy cancer cells or shrink tumors. It
is a common and effective treatment modality for various types of cancer,
including but not limited to neuroblastoma, prostate cancer, breast cancer,
lung cancer, and brain tumors. Radiation therapy works by damaging the DNA
inside cancer cells, preventing them from growing and dividing. Radiation therapy can cause side effects,
which vary depending on the treated area and the dose. Common side effects
include skin irritation, fatigue, nausea, and temporary hair loss in the
treated area. These side effects are usually temporary and can be managed with
medications or lifestyle adjustments. Patients receiving radiation therapy are closely monitored throughout
treatment. After treatment, follow-up appointments and imaging scans are
conducted to assess the response and ensure that the cancer has been
effectively treated.
Based on Region, North
America dominated the Global Pediatric
Neuroblastoma Treatment Market. North America has strong pediatric
cancer awareness and advocacy organizations that work to raise awareness, fund
research, and support families affected by neuroblastoma. This can lead to
increased funding and attention to this cancer. Many patients in North America
have health insurance coverage, which can facilitate access to expensive cancer
treatments and ensure that families do not face catastrophic healthcare costs. Leading
medical centers in North America often employ a multidisciplinary approach to
pediatric neuroblastoma treatment, involving teams of specialists in pediatric
oncology, surgery, radiation therapy, and other fields to provide comprehensive
care. Patients from other regions of the world may seek treatment in North America
due to its reputation for advanced medical care, further contributing to the
region's prominence in the market.
The Asia-pacific region
witnesses the fastest growth in the Global Pediatric Neuroblastoma Treatment Market. The Asia-Pacific
region has seen an increase in the incidence of pediatric neuroblastoma, like
global trends. This rising incidence contributes to the growing demand for
neuroblastoma treatment in the region. The Asia-Pacific region is home to a
significant portion of the world's population, including a large pediatric
population. With a growing population, there is an increased pool of potential
pediatric neuroblastoma patients. Many countries in the Asia-Pacific region
have been investing in improving their healthcare infrastructure. This includes
expanding access to specialized pediatric oncology centers, advanced diagnostic
tools, and treatment options. Clinical research and participation in
international clinical trials have expanded in the Asia-Pacific region. This
provides patients with access to cutting-edge treatments and therapies,
contributing to the growth of the pediatric neuroblastoma treatment market.
Growing awareness among healthcare providers and the public about childhood
cancers and the importance of early diagnosis has led to more cases being
detected and treated promptly. Some countries in the Asia-Pacific region have
initiated government-led programs and initiatives to address childhood cancer,
including neuroblastoma. These programs often focus on improving early
diagnosis, treatment access, and support for affected families.
Some of the major companies operating in the Global Pediatric Neuroblastoma Treatment Market include:
- United Therapeutics
Corporation
- APEIRON Biologics AG
- Baxter International Inc.
- Cell Ectar Biosciences Inc.
- Pfizer Inc.
- Bayer AG
- Provectus
Biopharmaceuticals Inc.
- Sartorius AG
- Amgen Inc.
- F. Hoffmann-La Roche AG
Download Free Sample Report
Customers can also request 10% free customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand for Pediatric Neuroblastoma
Treatment. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Pediatric Neuroblastoma Treatment Market in the forecast
period," said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Pediatric
Neuroblastoma Treatment Market – Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2018-2028, Segmented By Treatment Type (Chemotherapy, Immunotherapy, Radiation
Therapy, and Others), and by End-User (Hospitals, Specialty Clinics and Others),
by region, and Competition evaluated the future growth potential of
Global Pediatric Neuroblastoma Treatment Market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide innovative market intelligence and help decision makers take
sound investment decisions. Besides, the report also identifies and analyzes
the emerging trends along with essential drivers, challenges, and opportunities
in Global Pediatric Neuroblastoma Treatment Market.
Contact
TechSci
Research LLC
420
Lexington Avenue,
Suite 300,
New York,
United
States- 10170
M:
+13322586602
Email: [email protected]
Website: https://www.techsciresearch.com